These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16291763)

  • 41. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
    Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
    Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.
    Hostetler JB; Sharma S; Bartholdson SJ; Wright GJ; Fairhurst RM; Rayner JC
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004264. PubMed ID: 26701602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.
    Wongkidakarn S; McHenry AM; Sattabongkot J; Adams JH; Chootong P
    PLoS One; 2016; 11(5):e0154577. PubMed ID: 27145131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.
    Nicolete VC; Frischmann S; Barbosa S; King CL; Ferreira MU
    J Infect Dis; 2016 Nov; 214(10):1539-1546. PubMed ID: 27578850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys.
    Rojas Caraballo J; Delgado G; Rodriguez R; Patarroyo MA
    Vaccine; 2007 May; 25(18):3713-21. PubMed ID: 17240494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
    Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
    Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.
    Zakeri S; Babaeekhou L; Mehrizi AA; Abbasi M; Djadid ND
    Am J Trop Med Hyg; 2011 Jun; 84(6):944-50. PubMed ID: 21633032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2.
    Kocken CH; Dubbeld MA; Van Der Wel A; Pronk JT; Waters AP; Langermans JA; Thomas AW
    Infect Immun; 1999 Jan; 67(1):43-9. PubMed ID: 9864194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
    Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
    Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
    Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
    Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.
    Valizadeh V; Zakeri S; Mehrizi AA; Mirkazemi S; Djadid ND
    Med Microbiol Immunol; 2016 Feb; 205(1):85-95. PubMed ID: 26243337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.
    Saul A; Hensmann M; Sattabongkot J; Collins WE; Barnwell JW; Langermans JA; Wu Y; Long CA; Dubovsky F; Thomas AW
    Parasite Immunol; 2007 Oct; 29(10):525-33. PubMed ID: 17883455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
    Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
    Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.
    Céspedes N; Arévalo-Herrera M; Felger I; Reed S; Kajava AV; Corradin G; Herrera S
    Vaccine; 2013 Oct; 31(42):4923-30. PubMed ID: 23954378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human antibodies against DBP.
    Richards JS; Ramsland PA
    Nat Microbiol; 2019 Sep; 4(9):1428-1429. PubMed ID: 31439930
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
    Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
    Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
    Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
    Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan.
    Hoque MR; Elfaki MMA; Ahmed MA; Lee SK; Muh F; Ali Albsheer MM; Hamid MMA; Han ET
    Malar J; 2018 Aug; 17(1):297. PubMed ID: 30119671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development.
    Sampath S; Carrico C; Janes J; Gurumoorthy S; Gibson C; Melcher M; Chitnis CE; Wang R; Schief WR; Smith JD
    PLoS Pathog; 2013; 9(6):e1003420. PubMed ID: 23853575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region.
    Kano FS; Sanchez BA; Sousa TN; Tang ML; Saliba J; Oliveira FM; Nogueira PA; Gonçalves AQ; Fontes CJ; Soares IS; Brito CF; Rocha RS; Carvalho LH
    Trop Med Int Health; 2012 Aug; 17(8):989-1000. PubMed ID: 22643072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.